Published in Proc Natl Acad Sci U S A on August 01, 1985
Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J (1990) 3.27
Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development (1996) 2.88
Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol (1987) 2.63
The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol (1986) 2.50
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol (1991) 2.38
The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol (1990) 2.36
The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol (1987) 2.04
Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol (1988) 1.97
Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol (1989) 1.93
Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos. J Cell Biol (1989) 1.88
Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J (1990) 1.87
Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J (1997) 1.85
Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol (1987) 1.79
Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J (1996) 1.70
Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol (2001) 1.68
Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J Clin Invest (1991) 1.59
Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin. J Cell Biol (1988) 1.49
A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J (1997) 1.47
The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol (1995) 1.47
Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta. J Cell Biol (1988) 1.44
Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol (1989) 1.41
alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor. J Cell Biol (1995) 1.35
Plasminogen activator and mouse spermatozoa: urokinase synthesis in the male genital tract and binding of the enzyme to the sperm cell surface. J Cell Biol (1987) 1.33
In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol (1991) 1.33
Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells. J Cell Biol (1987) 1.32
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl Acad Sci U S A (1989) 1.29
High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci U S A (1994) 1.26
Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J Cell Biol (1991) 1.23
An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J Clin Invest (1991) 1.23
Modulation of urokinase plasminogen activator gene expression during the transition from quiescent to proliferative state in normal mouse cells. EMBO J (1986) 1.19
Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol (1993) 1.18
Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer. Exp Cell Res (2004) 1.16
Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest (1987) 1.15
Human neutrophil plasminogen activator is localized in specific granules and is translocated to the cell surface by exocytosis. J Exp Med (1986) 1.13
Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. Biochem J (1995) 1.11
Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J Cell Biol (1991) 1.10
The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J (1994) 1.09
Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest (1991) 1.09
The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci U S A (1994) 1.08
Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J Clin Invest (1995) 1.08
Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells. Cell Regul (1990) 1.06
Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes. J Clin Invest (1996) 1.06
Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor. J Cell Biol (1991) 1.06
Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. Neoplasia (2009) 1.05
Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. J Clin Invest (1993) 1.04
Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res (2010) 1.04
Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regul (1991) 1.03
Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochem J (2001) 0.99
A high-affinity receptor for urokinase plasminogen activator on human keratinocytes: characterization and potential modulation during migration. Cell Regul (1990) 0.99
Regulation of plasminogen receptor expression on human monocytes and monocytoid cell lines. J Cell Biol (1990) 0.99
Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells. EMBO J (1991) 0.99
Urokinase receptor-dependent and -independent p56/59(hck) activation state is a molecular switch between myelomonocytic cell motility and adherence. EMBO J (1999) 0.96
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Eur J Nucl Med Mol Imaging (2007) 0.96
The urokinase receptor can be induced by Borrelia burgdorferi through receptors of the innate immune system. Infect Immun (2003) 0.94
Characterization of 125I-tissue plasminogen activator binding to cerebellar granule neurons. J Cell Biol (1989) 0.94
Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc Natl Acad Sci U S A (1989) 0.93
Characterization of a Drosophila protein that binds both epidermal growth factor and insulin-related growth factors. J Cell Biol (1987) 0.91
Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer (2011) 0.90
Modulation of cellular migration and survival by c-Myc through the downregulation of urokinase (uPA) and uPA receptor. Mol Cell Biol (2010) 0.89
Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist. Theranostics (2013) 0.88
Targeting the urokinase plasminogen activator receptor enhances gene transfer to human airway epithelia. J Clin Invest (2000) 0.87
Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells. Biochem J (1995) 0.87
Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR). Bioconjug Chem (2009) 0.84
A deficiency of uPAR alters endothelial angiogenic function and cell morphology. Vasc Cell (2011) 0.84
Transformation-dependent activation of urokinase-type plasminogen activator by a plasmin-independent mechanism: involvement of cell surface membranes. Proc Natl Acad Sci U S A (1991) 0.83
Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility. J Cell Biol (1997) 0.83
Assignment of the urokinase-type plasminogen activator receptor gene (PLAUR) to chromosome 19q13.1-q13.2. Am J Hum Genet (1992) 0.82
A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance. J Biol Chem (2010) 0.81
Binding of urokinase to specific receptor sites on human breast cancer membranes. Br J Cancer (1987) 0.80
Role of plasminogen activator in pemphigus vulgaris. Am J Pathol (1989) 0.79
Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion. Br J Cancer (1993) 0.79
Urokinase has direct catalytic activity against fibrinogen and renders it less clottable by thrombin. J Clin Invest (1990) 0.79
Differentiation-Associated Downregulation of Poly(ADP-Ribose) Polymerase-1 Expression in Myoblasts Serves to Increase Their Resistance to Oxidative Stress. PLoS One (2015) 0.79
Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: A potential therapeutic target for human stomach cancer. Korean J Intern Med (2006) 0.78
uPAR: a modulator of VEGF-induced angiogenesis. Cell Adh Migr (2012) 0.78
Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells. Cell Regul (1991) 0.77
Bound plasminogen is rate-limiting for cell-surface-mediated activation of plasminogen by urokinase. Biochem J (1995) 0.77
Formation of polyomavirus-like particles with different VP1 molecules that bind the urokinase plasminogen activator receptor. J Virol (2003) 0.77
Challenges for drug discovery - a case study of urokinase receptor inhibition. Comb Chem High Throughput Screen (2009) 0.77
Human retinal pigment epithelial lysis of extracellular matrix: functional urokinase plasminogen activator receptor, collagenase, and elastase. Trans Am Ophthalmol Soc (2002) 0.76
Three types of human lung tumour cell lines can be distinguished according to surface expression of endogenous urokinase and their capacity to bind exogenous urokinase. Br J Cancer (1992) 0.75
Decreased urokinase receptor expression by overexpression of the plasminogen activator in a colon cancer cell line. Biochem J (1992) 0.75
Biophysical Mechanisms Mediating Fibrin Fiber Lysis. Biomed Res Int (2017) 0.75
Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor. Pharmacology (2009) 0.75
Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin. Biochem J (1993) 0.75
Binding of tissue plasminogen activator to human endothelial cells. Importance of the B-chain as a ligand. Biochem J (1992) 0.75
Binding of tissue plasminogen activator to human aortic endothelial cells. Biochem J (1990) 0.75
Porphyromonas gingivalis-derived RgpA-Kgp Complex Activates the Macrophage Urokinase Plasminogen Activator System: IMPLICATIONS FOR PERIODONTITIS. J Biol Chem (2015) 0.75
Isolation and characterization of cell lines with reduced urokinase binding. Clin Exp Metastasis (2000) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer (1976) 14.08
Epidermal growth factor and a new derivative. Rapid isolation procedures and biological and chemical characterization. J Biol Chem (1972) 10.86
Two mRNAs can be produced from a single immunoglobulin mu gene by alternative RNA processing pathways. Cell (1980) 9.86
Secretion of plasminogen activator by stimulated macrophages. J Exp Med (1974) 8.82
Autocrine secretion and malignant transformation of cells. N Engl J Med (1980) 7.49
Transient expression of interleukin 2 receptors. Consequences for T cell growth. J Exp Med (1983) 5.82
Phagocytosis by human monocytes. Blood (1968) 3.96
A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol (1985) 3.62
Fibrinolysis associated with oncogenic transformation. Requirement of plasminogen for correlated changes in cellular morphology, colony formation in agar, and cell migration. J Exp Med (1973) 3.16
Antibodies to plasminogen activator inhibit human tumor metastasis. Cell (1983) 2.82
Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med (1984) 2.78
Resolution of high and low affinity epidermal growth factor receptors. Inhibition of high affinity component by low temperature, cycloheximide, and phorbol esters. J Biol Chem (1982) 2.54
Urokinase an activator of plasminogen from human urine. I. Isolation and properties. Biochim Biophys Acta (1957) 2.30
Transforming growth factor-beta controls receptor levels for epidermal growth factor in NRK fibroblasts. Cell (1984) 2.30
The role of proteinases in cellular invasiveness. Biochim Biophys Acta (1983) 2.21
The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. Hoppe Seylers Z Physiol Chem (1982) 2.14
A proenzyme form of human urokinase. J Biol Chem (1982) 1.98
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry (1982) 1.85
Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA. Proc Natl Acad Sci U S A (1984) 1.80
Isolation and characterization of urokinase from human plasma. J Biol Chem (1982) 1.47
Induction of antibody-dependent and nonspecific tumor killing in human monocytic leukemia cells by nonlymphocyte factors and phorbol ester. Cell Immunol (1982) 1.44
The insulin receptor of a human monocyte-like cell line: characterization and function. Endocrinology (1984) 1.16
Mathematics of hormone-receptor interaction. I. Basic principles. Adv Exp Med Biol (1973) 1.13
Structural relationship between human high and low molecular mass urokinase. Hoppe Seylers Z Physiol Chem (1982) 1.10
Monoclonal antibodies to human urokinase identify the single-chain pro-urokinase precursor. Proc Natl Acad Sci U S A (1984) 1.10
[LeuB24]insulin and [AlaB24]insulin: altered structures and cellular processing of B24-substituted insulin analogs. Proc Natl Acad Sci U S A (1982) 1.04
Plasminogen activator is an apparent lymphocyte mitogen. J Immunol (1981) 1.01
Human monocyte plasminogen activator production: correlation to altered M phi-T lymphocyte interaction. J Immunol (1982) 0.84
Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A (1986) 12.14
Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature (1985) 10.13
Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem (1983) 9.32
Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci U S A (1987) 6.76
Transforming growth factor-beta: biological function and chemical structure. Science (1986) 5.08
Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol (1986) 3.77
125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic? Eur Respir J (2007) 3.67
Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat Cell Biol (2001) 3.63
Guidelines for the management of adult lower respiratory tract infections. Eur Respir J (2005) 3.51
Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J (1990) 3.27
Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect (2011) 2.99
A link between cyclin A expression and adhesion-dependent cell cycle progression. Science (1993) 2.96
Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. J Cell Sci (2001) 2.91
Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation (1995) 2.91
Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol (2001) 2.80
The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem (1987) 2.73
Nucleotide sequence of the attenuator region of the histidine operon of Escherichia coli K-12. Proc Natl Acad Sci U S A (1978) 2.71
Integrin-dependent activation of MAP kinase: a link to shape-dependent cell proliferation. Mol Biol Cell (1995) 2.68
Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem (1991) 2.68
Cellular transformation by coordinated action of three peptide growth factors from human platelets. Nature (1984) 2.66
Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J (1992) 2.65
Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol (1987) 2.63
Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol (1996) 2.56
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol (1991) 2.38
Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell (1986) 2.38
Transforming growth factor-beta controls receptor levels for epidermal growth factor in NRK fibroblasts. Cell (1984) 2.30
Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays (2000) 2.22
Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol (2000) 2.18
The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci U S A (2002) 2.14
The human urokinase-plasminogen activator gene and its promoter. Nucleic Acids Res (1985) 2.14
Antibiotic prescribing for adults with acute cough/lower respiratory tract infection: congruence with guidelines. Eur Respir J (2011) 2.13
Induction of transforming growth factor-alpha in activated human alveolar macrophages. Cell (1988) 2.13
Induction of functional inducible nitric oxide synthase in monocytes of patients with congestive heart failure. Link with tumour necrosis factor-alpha. Eur Heart J (1999) 2.12
Cytoskeletal integrity is required throughout the mitogen stimulation phase of the cell cycle and mediates the anchorage-dependent expression of cyclin D1. Mol Biol Cell (1996) 2.12
The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J Clin Invest (2001) 2.04
Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp. Antimicrob Agents Chemother (1984) 2.01
Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J (2002) 1.98
Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J (1987) 1.98
Application of a computerised method to measure static pressure volume curve in acute respiratory distress syndrome. Intensive Care Med (2000) 1.95
Prep1, a novel functional partner of Pbx proteins. EMBO J (1998) 1.94
The subcellular localization of PBX1 and EXD proteins depends on nuclear import and export signals and is modulated by association with PREP1 and HTH. Genes Dev (1999) 1.93
The novel homeoprotein Prep1 modulates Pbx-Hox protein cooperativity. EMBO J (1998) 1.93
Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J (1990) 1.87
A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J (1992) 1.81
Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA. Proc Natl Acad Sci U S A (1984) 1.80
Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med (2001) 1.79
Inhibition of RNA polymerase by streptolydigin. Nat New Biol (1971) 1.76
Analysis of IMGSAC autism susceptibility loci: evidence for sex limited and parent of origin specific effects. J Med Genet (2005) 1.74
European union standards for tuberculosis care. Eur Respir J (2012) 1.73
Alpha5beta1 integrin controls cyclin D1 expression by sustaining mitogen-activated protein kinase activity in growth factor-treated cells. Mol Biol Cell (1999) 1.73
Chlamydia pneumoniae: crossing the barriers? Eur Respir J (2004) 1.70
Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res (1988) 1.70
Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J (1996) 1.70
Biochemical and regulatory properties of Escherichia coli K-12 hisT mutants. J Bacteriol (1977) 1.69
Segmental expression of Hoxb2 in r4 requires two separate sites that integrate cooperative interactions between Prep1, Pbx and Hox proteins. Development (2000) 1.69
Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood (2000) 1.69
Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett (1986) 1.68
Structure and function of epidermal growth factor-like regions in proteins. FEBS Lett (1988) 1.66
Increased secretion of type beta transforming growth factor accompanies viral transformation of cells. Mol Cell Biol (1985) 1.65
Interaction between histidyl transfer ribonucleic acid and the first enzyme for histidine biosynthesis of Salmonella typhimurium. J Bacteriol (1970) 1.64
Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J (1997) 1.64
Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin Cancer Res (2000) 1.60
Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1. J Cell Biol (2001) 1.54
The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem (1991) 1.52
The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci (2007) 1.51
Isolation of transducing bacteriophages for the histidine and isoleucine-valine operons in Escherichia coli K-12. J Bacteriol (1972) 1.50
A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature (1997) 1.50
Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J Biol Chem (1986) 1.49
A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem (1988) 1.49
A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J (1997) 1.47
Screening of nine candidate genes for autism on chromosome 2q reveals rare nonsynonymous variants in the cAMP-GEFII gene. Mol Psychiatry (2003) 1.47
Multicenter comparison trial of DNA extraction methods and PCR assays for detection of Chlamydia pneumoniae in endarterectomy specimens. J Clin Microbiol (2001) 1.46
Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta. J Cell Biol (1988) 1.44
The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia. Eur Respir J (2008) 1.43
The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem (1990) 1.43
A40926, a new glycopeptide antibiotic with anti-Neisseria activity. Antimicrob Agents Chemother (1987) 1.42
Identification, nucleotide sequence and expression of the regulatory region of the histidine operon of Escherichia coli K-12. Nucleic Acids Res (1981) 1.41
Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol (1989) 1.41
Interaction between the first enzyme for histidine biosynthesis and histidyl transfer ribonucleic acid. J Bacteriol (1971) 1.41
Antibiotic prescribing for discoloured sputum in acute cough/lower respiratory tract infection. Eur Respir J (2011) 1.39
Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res (1999) 1.38
A 13-year-old female with shortness of breath and pleuritic chest pain. Eur Respir J (2006) 1.38
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res (1998) 1.38
Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene (1991) 1.37
Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results. J Infect Dis (2000) 1.36
alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor. J Cell Biol (1995) 1.35
Transcription factor PEA3 participates in the induction of urokinase plasminogen activator transcription in murine keratinocytes stimulated with epidermal growth factor or phorbol-ester. Nucleic Acids Res (1990) 1.35
In vivo and in vitro detection of the leader RNA of the histidine operon of Escherichia coli K-12. Proc Natl Acad Sci U S A (1981) 1.34